Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis (Review)
- Authors:
- Ramadevi Subramani
- Laxman Gangwani
- Sushmita Bose Nandy
- Arunkumar Arumugam
- Munmun Chattopadhyay
- Rajkumar Lakshmanaswamy
-
Affiliations: Department of Biomedical Sciences, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, 5001 El Paso Drive, El Paso, TX 79905, USA - Published online on: August 21, 2015 https://doi.org/10.3892/ijo.2015.3129
- Pages: 1203-1210
-
Copyright: © Subramani et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Moniri MR, Dai LJ and Warnock GL: The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells. Cancer Gene Ther. 21:12–23. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Michaud DS: Epidemiology of pancreatic cancer. Minerva Chir. 59:99–111. 2004.PubMed/NCBI | |
|
Tamburrino A, Piro G, Carbone C, Tortora G and Melisi D: Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front Pharmacol. 4:562013. View Article : Google Scholar : PubMed/NCBI | |
|
Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, et al: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 4:437–450. 2003. View Article : Google Scholar | |
|
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI | |
|
Cheng H1, Shi S, Cai X, Long J, Xu J, Liu C and Yu X: microRNA signature for human pancreatic cancer invasion and metastasis. Exp Ther Med. 4:181–187. 2012.PubMed/NCBI | |
|
Longati P, Jia X, Eimer J, Wagman A, Witt MR, Rehnmark S, Verbeke C, Toftgård R, Löhr M and Heuchel RL: 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC Cancer. 13:952013. View Article : Google Scholar : PubMed/NCBI | |
|
Qazi AM1, Gruzdyn O, Semaan A, Seward S, Chamala S, Dhulipala V, Sethi S, Ali-Fehmi R, Philip PA, Bouwman DL, et al: Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101. Surgery. 152:704–711; discussion 711–713. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Borja-Cacho D, Jensen EH, Saluja AK, Buchsbaum DJ and Vickers SM: Molecular targeted therapies for pancreatic cancer. Am J Surg. 196:430–441. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Dai ZJ, Gao J, Kang HF, Ma YG, Ma XB, Lu WF, Lin S, Ma HB, Wang XJ and Wu WY: Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells. Drug Des Devel Ther. 7:149–159. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Papaconstantinou IG, Lykoudis PM, Gazouli M, Manta A, Polymeneas G and Voros D: A review on the role of microRNA in biology, diagnosis, and treatment of pancreatic adenocarcinoma. Pancreas. 41:671–677. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xu C, Ping Y and Li X, Zhao H, Wang L, Fan H, Xiao Y and Li X: Prioritizing candidate disease miRNAs by integrating phenotype associations of multiple diseases with matched miRNA and mRNA expression profiles. Mol Biosyst. 10:2800–2809. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Qiu C, Chen G and Cui Q: Towards the understanding of microRNA and environmental factor interactions and their relationships to human diseases. Sci Rep. 2:3182012. View Article : Google Scholar : PubMed/NCBI | |
|
Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ and Wang K: The microRNA spectrum in 12 body fluids. Clin Chem. 56:1733–1741. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Humeau M, Torrisani J and Cordelier P: miRNA in clinical practice: Pancreatic cancer. Clin Biochem. 46:933–936. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Vlastos G and Verkooijen HM: Minimally invasive approaches for diagnosis and treatment of early-stage breast cancer. Oncologist. 12:1–10. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Sicard F, Gayral M, Lulka H, Buscail L and Cordelier P: Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther. 21:986–994. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cai B, An Y, Lv N, Chen J, Tu M, Sun J, Wu P, Wei J, Jiang K and Miao Y: miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. Oncol Rep. 29:1769–1776. 2013.PubMed/NCBI | |
|
Kawaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T, Hirajima S, et al: Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer. 108:361–369. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang WS, Liu LX, Li GP, Chen Y, Li CY, Jin DY and Wang XL: Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer. Cancer Prev Res (Phila). 6:331–338. 2013. View Article : Google Scholar | |
|
Huang J, Egger M, Grizzle W and McNally L: MicroRNA-100 regulates IGF1-receptor expression in metastatic pancreatic cancer cells. Biotech Histochem. 88:397–402. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B, Quera A, Bandres E, Garcia-Foncillas J and Ramirez J: miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 30:1903–1909. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K, Luo J, Chen Z, Meng Z and Liu L: Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene. 33:514–524. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM and Chen J: The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis. 31:1726–1733. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Delpu Y, Lulka H, Sicard F, Saint-Laurent N, Lopez F, Hanoun N, Buscail L, Cordelier P and Torrisani J: The rescue of miR-148a expression in pancreatic cancer: An inappropriate therapeutic tool. PLoS One. 8:e555132013. View Article : Google Scholar : PubMed/NCBI | |
|
Druz A, Chen YC, Guha R, Betenbaugh M, Martin SE and Shiloach J: Large-scale screening identifies a novel microRNA, miR-15a-3p, which induces apoptosis in human cancer cell lines. RNA Biol. 10:287–300. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hou B, Jian Z, Chen S, Ou Y, Li S and Ou J: Expression of miR-216a in pancreatic cancer and its clinical significance. Nan Fang Yi Ke Da Xue Xue Bao. 32:1628–1631. 2012.PubMed/NCBI | |
|
Jiao LR, Frampton AE, Jacob J, Pellegrino L, Krell J, Giamas G, Tsim N, Vlavianos P, Cohen P, Ahmad R, et al: MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS One. 7:e320682012. View Article : Google Scholar : PubMed/NCBI | |
|
Drakaki A and Iliopoulos D: MicroRNA-gene signaling pathways in pancreatic cancer. Biomed J. 36:200–208. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J and Sen S: MicroRNA functional network in pancreatic cancer: From biology to biomarkers of disease. J Biosci. 36:481–491. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen TD: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar | |
|
Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM, et al: MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 297:1901–1908. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q and Chen C: Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg. 33:698–709. 2009. View Article : Google Scholar | |
|
Mees ST, Mardin WA, Wendel C, Baeumer N, Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M and Haier J: EP300 - a miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas. Int J Cancer. 126:114–124. 2010. View Article : Google Scholar | |
|
Szafranska AE1, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E and Hahn SA: MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 26:4442–4452. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Szafranska AE1, Doleshal M, Edmunds HS, Gordon S, Luttges J, Munding JB, Barth RJ Jr, Gutmann EJ, Suriawinata AA, Marc Pipas J, Tannapfel A, et al: Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem. 54:1716–1724. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang S, Cai X, Huang F, Zhong W and Yu Z: Effect of trichostatin a on viability and microRNA expression in human pancreatic cancer cell line BxPC-3. Exp Oncol. 30:265–268. 2008.PubMed/NCBI | |
|
Gironella M1, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, et al: Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA. 104:16170–16175. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Pawa N, Arulampalam T and Norton JD: Screening for colorectal cancer: Established and emerging modalities. Nat Rev Gastroenterol Hepatol. 8:711–722. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lee KJ, Yi SW, Chung MJ, Park SW, Song SY, Chung JB and Park JY: Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J. 54:643–649. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Gao J, Du Y, Li Z, Ren Y, Gu J, Wang X, Gong Y, Wang W and Kong X: Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer. 131:683–691. 2012. View Article : Google Scholar | |
|
Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM and Sen S: MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2:807–813. 2009. View Article : Google Scholar | |
|
Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG and Maitra A: Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology. 10:66–73. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Park JY, Helm J, Coppola D, Kim D, Malafa M and Kim SJ: MicroRNAs in pancreatic ductal adenocarcinoma. World J Gastroenterol. 17:817–827. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Morimura R, Komatsu S, Ichikawa D, Takeshita H, Tsujiura M, Nagata H, Konishi H, Shiozaki A, Ikoma H, Okamoto K, et al: Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer. 105:1733–1740. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Keklikoglou I, Hosaka K, Bender C, Bott A, Koerner C, Mitra D, Will R, Woerner A, Muenstermann E, Wilhelm H, et al: MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene. Dec 15–2014, http://dx.doi.org/10.1038/onc.2014.408. | |
|
Song S and Ajani JA: The role of microRNAs in cancers of the upper gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 10:109–118. 2013. View Article : Google Scholar | |
|
Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT and Maitra A: Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther. 10:1470–1480. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT and Maitra A: Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma. Mol Carcinog. 53:711–712. 2013. | |
|
Liu C, Cheng H, Shi S, Cui X, Yang J, Chen L, Cen P, Cai X, Lu Y, Wu C, et al: MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3. Curr Mol Med. 13:467–478. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
MacKenzie TN, Mujumdar N, Banerjee S, Sangwan V, Sarver A, Vickers S, Subramanian S and Saluja AK: Triptolide induces the expression of miR-142-3p: A negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation. Mol Cancer Ther. 12:1266–1275. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sun T, Kong X, Du Y and Li Z: Aberrant MicroRNAs in pancreatic cancer: Researches and clinical implications. Gastroenterol Res Pract. 2014:3865612014. View Article : Google Scholar : PubMed/NCBI | |
|
Di Leva G and Croce CM: miRNA profiling of cancer. Curr Opin Genet Dev. 23:3–11. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kong X, Du Y, Wang G, Gao J, Gong Y, Li L, Zhang Z, Zhu J, Jing Q, Qin Y and Li Z: Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci. 56:602–609. 2011. View Article : Google Scholar | |
|
Frampton AE, Krell J, Jacob J, Stebbing J, Jiao LR and Castellano L: microRNAs as markers of survival and chemo-resistance in pancreatic ductal adenocarcinoma. Expert Rev Anticancer Ther. 11:1837–42. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mardin WA and Mees ST: MicroRNAs: Novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma? Ann Surg Oncol. 16:3183–9. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Papaconstantinou IG, Manta A, Gazouli M, Lyberopoulou A, Lykoudis PM, Polymeneas G and Voros D: Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas. 42:67–71. 2013. View Article : Google Scholar | |
|
Schultz NA, Andersen KK, Roslind A, Willenbrock H, Wojdemann M and Johansen JS: Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index. World J Surg. 36:2699–2707. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A, Falcone A, et al: MicroRNA-21 in pancreatic cancer: Correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 70:4528–4538. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bauer AS, Keller A, Costello E, Greenhalf W, Bier M, Borries A, Beier M, Neoptolemos J, Büchler M, Werner J, et al: Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. PLoS One. 7:e341512012. View Article : Google Scholar : PubMed/NCBI | |
|
Costello E, Greenhalf W and Neoptolemos JP: New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol. 9:435–444. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Giovannetti E1, van der Velde A, Funel N, Vasile E, Perrone V, Leon LG, De Lio N, Avan A, Caponi S, Pollina LE, et al: High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. PLoS One. 7:e491452012. View Article : Google Scholar : PubMed/NCBI | |
|
Preis M, Gardner TB, Gordon SR, Pipas JM, Mackenzie TA, Klein EE, Longnecker DS, Gutmann EJ, Sempere LF and Korc M: MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res. 17:5812–5821. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, Wang Z, Philip PA and Sarkar FH: Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 70:3606–3617. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yu J1, Ohuchida K, Mizumoto K, Sato N, Kayashima T, Fujita H, Nakata K and Tanaka M: MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer. 9:1692010. View Article : Google Scholar : PubMed/NCBI | |
|
Ohuchida K, Mizumoto K, Kayashima T, Fujita H, Moriyama T, Ohtsuka T, Ueda J, Nagai E, Hashizume M and Tanaka M: MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol. 18:2381–2387. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P and Taubert H: Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 126:73–80. 2010. View Article : Google Scholar | |
|
Hasegawa S, Eguchi H, Nagano H, Konno M, Tomimaru Y, Wada H, Hama N, Kawamoto K, Kobayashi S, Nishida N, et al: MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Br J Cancer. 111:1572–1580. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Paik WH, Kim HR, Park JK, Song BJ, Lee SH and Hwang JH: Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol. Anticancer Res. 33:1473–1481. 2013.PubMed/NCBI | |
|
Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM, Fortes P and Garcia-Foncillas J: MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells. 29:1661–1671. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tan L, Sui X, Deng H and Ding M: Holoclone forming cells from pancreatic cancer cells enrich tumor initiating cells and represent a novel model for study of cancer stem cells. PLoS One. 6:e233832011. View Article : Google Scholar : PubMed/NCBI | |
|
Mazur PK and Siveke JT: Genetically engineered mouse models of pancreatic cancer: Unravelling tumour biology and progressing translational oncology. Gut. 61:1488–1500. 2012. View Article : Google Scholar | |
|
Choi SY, Lin D, Gout PW, Collins CC, Xu Y and Wang Y: Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Adv Drug Deliv Rev. 79–80. 222–237. 2014. | |
|
Mazur PK, Herner A, Neff F and Siveke JT: Current methods in mouse models of pancreatic cancer. Methods Mol Biol. 1267:185–215. 2015. View Article : Google Scholar : PubMed/NCBI |
